China
Africa
Explore chapters and articles related to this topic
Introductory Remarks
Published in Dongyou Liu, Tumors and Cancers, 2017
Under the auspices of the World Health Organization (WHO), the International Classification of Diseases for Oncology, third edition (ICD-O-3) [6], has designed a five-digit system for classifying tumors, with the first four digits being the morphology code and the fifth digit being the behavior code [6]. The fifth digit behavior codes for neoplasms range from 0 (benign), 1 (benign or malignant), 2 (carcinoma in situ), 3 (malignant, primary site), 6 (malignant, metastatic site) to 9 (malignant, primary or metastatic site). For example, chondroma has an IDC-O-3 code of 9220/0 and is considered a benign bone tumor; multiple chondromatosis (a subtype of chondroma) has an IDC-O-3 code of 9220/1 and is an intermediate grade bone tumor with the potential for malignant transformation; and central chondrosarcoma has an IDC-O-3 code of 9220/3 and is considered a malignant bone tumor [6].
Introductory Remarks
Published in Dongyou Liu, Tumors and Cancers, 2017
Under the auspices of the World Health Organization (WHO), the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) [6] has designed a five-digit system to classify tumors, with the first four digits being morphology code and the fifth digit behavior code [6]. The fifth-digit behavior codes for neoplasms are 0, benign; 1, benign or malignant; 2, carcinoma in situ; 3, malignant, primary site; 6, malignant, metastatic site; and 9, malignant, primary or metastatic site. For example, chondroma has an IDC-O code of 9220/0 and is considered a benign bone tumor; multiple chondromatosis (a subtype of chondroma) has an IDC-O code of 9220/1 and is an intermediate-grade bone tumor with the potential for malignant transformation; and central chondrosarcoma has an IDC-O code of 9220/3 and is considered a malignant bone tumor [2,6].
Introductory Remarks
Published in Dongyou Liu, Tumors and Cancers, 2017
Under the auspices of the World Health Organization (WHO), the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) has utilized a five-digit system to classify tumors, with the first four digits being morphology code and the fifth digit being behavior code [4]. The fifth-digit behavior codes for neoplasms include the following range: /0 benign; /1 benign or malignant; /2 carcinoma in situ; /3 malignant, primary site; /6 malignant, metastatic site; and /9 malignant, primary or metastatic site. For example, meningioma has an IDC-O code of 9530/0 and is a WHO Grade I tumor; atypical meningioma has an IDC-O code of 9539/1 and is a WHO Grade II tumor; and anaplastic (malignant) meningioma has an IDC-O code of 9530/3 and is a WHO Grade III tumor [4].
Impact of primary tumor resection on the survival of patients with unresectable colon cancer liver metastasis at different colonic subsites: a propensity score matching analysis
Published in Acta Chirurgica Belgica, 2023
Jiefeng Zhao, Jinfeng Zhu, Chao Huang, Rongfa Yuan, Zhengming Zhu
Patients with UCCLM were extracted from the database using SEER*Stat (Version 8.3.8) software for the period 2010 to 2016. The selection criteria were as follows: (1) ICD-O-3 site codes: cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, and sigmoid colon; (2) ICD-O-3 behavior codes: malignant; (3) diagnostic confirmation: positive histology; (4) ICD-O-3 histology codes: adenocarcinoma (8140–8147, 8210–8211, 8220–8221, and 8260–8263), mucinous adenocarcinoma (8480–8481), and signet ring cell carcinoma (8490). The exclusion criteria were as follows: (1) incomplete PTR information; (2) metastatic sites apart from the liver; (3) non-histological diagnosis; (4) no first tumor; (5) previously had surgery for liver metastases; (6) survival months: unknown; (7) PTR codes: 26, 27, 28, and 29. Given that there were few cases of appendiceal and colorectal junction cancer with liver metastasis in the SEER database, such cases were not included in this study.
Lung cancer registries in Denmark, Finland, Norway and Sweden: a comparison and proposal for harmonization
Published in Acta Oncologica, 2023
A. Gouliaev, T. R. Rasmussen, N. Malila, L. Fjellbirkeland, L. Löfling, E. Jakobsen, S. O. Dalton, N. L. Christensen
Founded in 1952, the Finnish Cancer Registry (FCR) maintains the national population-based cancer registry on behalf of the Finnish Institute for Health and Welfare. Registration began in 1953 and reporting by treating hospitals and pathology laboratories became mandatory in 1961 [28]. All invasive cancer cases, including suspected cases should be reported to the registry. Since 2007, the International Classification of Diseases for Oncology (ICD-O-3) has been used for coding cancer cases to the FCR database, these data are converted to ICD-10 for reporting purposes. Reported data concerning tumor and disease stage should preferably be based on the TNM classification, but data is still often missing. Thus, based on the best available information received, lung cancer cases are classified as either localized, non-localized, or unknown [28].
Development and validation of a prognostic nomogram model in primary cutaneous and subcutaneous soft tissue angiosarcoma
Published in Journal of Dermatological Treatment, 2022
Jinqian Mao, Jin Hu, Yunfei Chen, Yiqing Li, Xiaoqin Run
Approximately 0.5/1,000,000 persons in the US have been diagnosed with angiosarcoma, with about 200 new cases reported every year (7). Although the causes of most cases are unknown, risk factors related to this sarcoma, include prior radiation, chemicals exposure, foreign material retention, chronic lymphedema, familial syndromes, arteriovenous fistula, ultraviolet ray exposure, and immunodeficiency (1,3,8). PCA and PSCA are rare. However, the number of cases was steadily growing, which might be attributed to enhanced diagnostic levels and more risk factors exposure. A sharp increase was observed in 2000 which was likely attributed to the 2000 International Classification of Diseases for Oncology version 3 (ICD-O-3). ICD-O-3 probably improved the diagnosis of patients that previously ignored. Although the number of patients was increasing yearly, our study found that the prognosis of patients in different years had no significant difference. Therefore, it is necessary to explore this tumor.